To the Editor: Dr Sundy and colleagues described the effect of pegloticase for treating chronic gout in patients refractory to allopurinol.
More here:
Pegloticase and Chronic Gout [Letters]
Pegloticase and Chronic Gout [Letters]
November 8, 2011 By
Pegloticase, Alternative Treatment For Chronic Gout Shows Greater Improvement In Symptoms
August 17, 2011 By
According to a study in the August 17 issue of JAMA, patients with severe, chronic gout who took pegloticase for 6 months as an alternative to conventional gout treatment that some patients may not respond to, showed greater improvements of uric acid levels as well as physical function and quality of life…
View article:
Pegloticase, Alternative Treatment For Chronic Gout Shows Greater Improvement In Symptoms
Pegloticase can improve clinical outcomes of patients with chronic gout
August 17, 2011 By
Injections of pegloticase, a modified porcine enzyme, can produce significant and sustained clinical improvements in 2 out of 5 patients with chronic gout that is resistant to conventional therapies, researchers report in the August 17, 2011, issue of JAMA.
Continue Reading:
Pegloticase can improve clinical outcomes of patients with chronic gout
Pegloticase Helps Patients With Severe, Chronic Gout
August 16, 2011 By
Individuals with severe, chronic gout who have not responded to conventional treatment may benefit from six-months’ worth of pegloticase treatment. Researchers from Duke University Medical Center, Durham, N.C., reported in JAMA (Journal of the American Medical Association) that individuals experienced better levels of uric acid as well as physical function, quality of life, and less pain. The …
Visit link:
Pegloticase Helps Patients With Severe, Chronic Gout
Medication for severe, chronic gout associated with improvement in symptoms
August 16, 2011 By
As an alternative to a conventional treatment for gout that some patients may not respond to, patients with severe, chronic gout who received the medication pegloticase for six months had greater improvement in measures of uric acid levels as well as physical function and quality of life, according to a study in the Aug. 17 issue of JAMA.
See the article here:
Medication for severe, chronic gout associated with improvement in symptoms
Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA(TM); Reports Fourth Quarter and Year-End 2010 Financial …
February 25, 2011 By
EAST BRUNSWICK, N.J. Feb. 25, 2011 /PRNewswire/ — Savient Pharmaceuticals, Inc.
Read more here:
Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA(TM); Reports Fourth Quarter and Year-End 2010 Financial …
Savient launches KRYSTEXXA in the U.S.
February 25, 2011 By
Savient Pharmaceuticals, Inc. today announced the official full U.S.
See the original post:
Savient launches KRYSTEXXA in the U.S.
Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA; Reports Fourth Quarter and Year-End 2010 Financial Results
February 25, 2011 By
Savient Pharmaceuticals, Inc. today announced the official full U.S. commercial launch of KRYSTEXXA⢠, which has been approved by the U.S
